Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a Bispecific Antibody Targeting Clinical Isolates of Acinetobacter baumannii

6 Jan 2023

Abstract excerpt

BACKGROUND: We previously reported developing 2 anticapsular monoclonal antibodies (mAbs) as a novel therapy for Acinetobacter baumannii infections. We sought to determine whether a bispecific mAb (bsAb) could improve avidity and efficacy while maximizing strain coverage in one molecule. METHODS: Humanized mAb 65 was cloned into a single-chain variable fragment and attached to humanized mAb C8, combining their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Bacterial Infections and Vaccines
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36617220
DOI: 10.1093/infdis/jiac499

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a Bispecific Antibody Targeting Clinical Isolates of Acinetobacter baumanniiPMID 36617220Read ↗

High-throughput single-cell analysis reveals fully human Omp38-specific monoclonal antibodies against Acinetobacter baumanniiSemantic proximity Read ↗

Single-Domain Antibodies as Potent Inhibitors of Clinically Relevant β-Lactamases in Multidrug-Resistant BacteriaSemantic proximity Read ↗

Development of novel multi-protein chimeric immunogens that protect against infection with the Lyme disease agent, Borreliella burgdorferiSemantic proximity Read ↗

Platform for Identifying Human Glycan-Specific Antibodies Against Bacterial Pathogens using Synthetic Glycan FragmentsSemantic proximity Read ↗

Improvement of affinity and potency of a monoclonal antibody against <i>Shigella flexneri</i> 3a O-antigen via phage display and whole-cell in-solution panningSemantic proximity Read ↗

Engineered antibodies targeted to bacterial surface integrate effector functions with toxin neutralization to provide superior efficacy against bacterial infectionsSemantic proximity Read ↗

A Broadly Conserved Protective Epitope on the Lyme Disease Vaccine Antigen, OspASemantic proximity Read ↗

Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.Semantic proximity Read ↗

A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein protects against infectionSemantic proximity Read ↗

Agnostic B cell selection approach identifies antibodies against K. pneumoniae that synergistically drive complement activation.Semantic proximity Read ↗

Fab2-SARAH: An Escherichia coli-Based Antibody Fragment Platform for Scalable, Cost-Effective In Vitro DiagnosticsSemantic proximity Read ↗

Uncovering bacterial pseudaminylation with pan-specific antibody toolsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.